Assessment of Late Gastrointestinal and Genitourinary Toxicities in Cervical and Endometrial Cancer Receiving Postoperative IMRT andor Brachytherapy

What this Trial Is About

Cervical cancer is the fourth most common cancer in women worldwide and the second most common in India, where cases have risen notably between 2018 and 2020. Endometrial cancer also poses a significant health burden in India, with thousands of new cases and associated deaths reported. Treatments for these cancers depend on clinical stage and risk factors, including surgery, chemotherapy, and radiation. Advanced radiation techniques like image-guided intensity-modulated radiotherapy IG-IMRT have been introduced to reduce acute and late toxicities, but there has been no assessment of treatment outcomes since its routine use began in 2020. This observational study aims to evaluate the clinical use of IG-IMRT and brachytherapy as postoperative adjuvant treatments for cervical and endometrial cancer patients treated at Tata Memorial Centre. It will audit patients receiving adjuvant IMRT with or without chemotherapy between January 2020 and June 2023. The study focuses on the incidence of moderate to severe gastrointestinal and genitourinary toxicities over three years. Participants will be monitored for three years to assess the occurrence of grade II or higher toxicities, acute side effects, disease-free and overall survival, and local regional cancer control. Researchers will also review radiation dose parameters to predict toxicity and compare findings with other institutional postoperative IMRT trials. Follow-up data and treatment details will be collected for comprehensive outcome analysis during the study period.

Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study